Stereotactic body radiation versus changing systemic therapy for oligoprogressive castrate-resistant prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-centre, randomized Phase II two-arm study comparing SBRT to all oligoprogressive extracranial sites while patients remain on their current systemic therapy versus standard of care which involves changing systemic therapy. Eligible patients have castration-resistant prostate cancer with fewer than 10 extracranial oligoprogressive metastatic lesions that can be safely treated with SBRT and have been on the same systemic therapy for more than three months. The trial measures biochemical control (e.g., PSA changes) and monitors quality of life and treatment-related toxicities during follow-up. The goal is to determine whether metastasis-directed SBRT can prolong disease control and delay the need for switching systemic therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>18 years
* Able to provide informed consent
* Histologic diagnosis of prostate adenocarcinoma
* Castrate Resistance Prostate Cancer
* Radiographic evidence of \<10 sites of extra-cranial OP metastatic lesions
* Receiving any line of ST for \>3 months
* All sites of OP disease are amenable to and can be safely treated with SBRT
* ECOG performance status 0-3

Exclusion Criteria:

* Evidence of spinal cord compression
* Contraindication to radiotherapy

Where it's running

• Princess Margaret Cancer Center
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Rachel Glicksman, MD — Princess Margaret Cancer Centre - University Health Network
• Study coordinator: Rachel Glicksman, MD
• Email: rachel.glicksman@uhn.ca
• Phone: 416-946-4501

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Focused radiotherapy to control a few growing melanoma spots

  This trial tries adding stereotactic or short-course radiotherapy to up to ten extracranial melanoma spots that are starting to grow while patients stay on their current systemic therapy to see if it delays overall disease progression.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07112170

• Targeted radiotherapy to up to three growing prostate cancer spots in castration‑resistant disease

  This trial will try adding targeted radiotherapy to up to three progressing spots to see if it can delay the next systemic treatment and extend disease control in men with oligoprogressive castration‑resistant prostate cancer.

  Recruiting Phase 2 University Medical Center Groningen · Groningen and 1 other locations · NCT07038304

• Stereotactic radiotherapy for limited progression in ER+/HER2- metastatic breast cancer

  This trial will try stereotactic body radiotherapy (SBRT) to treat 1–3 new resistant extracranial metastases in women with ER+/HER2- metastatic breast cancer on endocrine therapy and/or CDK4/6 inhibitors to see if local treatment lets them stay on their current systemic therapy longer.

  Recruiting at 5 sites Jules Bordet Institute · Brussels and 4 other locations · NCT06925984

• Stereotactic ablative radiotherapy versus single‑fraction palliative radiotherapy for oligoprogressive metastatic cancer

  This trial will test whether stereotactic ablative radiotherapy (SABR) works better than single‑fraction palliative radiotherapy (8 Gy) for people with 1–5 oligoprogressive metastatic lesions to delay the need for next‑line systemic therapy and improve quality of life.

  Recruiting British Columbia Cancer Agency · Surrey, British Columbia · NCT06918951

• Comparing radiotherapy with early switch to second-line therapy for oligoprogressive HCC

  This study is testing whether adding radiotherapy to ongoing treatment helps people with hepatocellular carcinoma who have limited cancer growth, compared to switching to a different treatment sooner.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06841172

• Combining radiotherapy with checkpoint inhibition for metastatic kidney cancer

  This study is testing if combining a new type of radiotherapy with an injectable treatment can help patients with advanced kidney cancer whose disease has continued to progress after previous therapies.

  Recruiting Phase 2 University of Texas Southwestern Medical Center · Dallas, Texas · NCT06601296

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.